Companies
Product/Regulation
FDA approves Mimrylo, the first hepcidin mimetic for adult polycythemia vera
The Food and Drug Administration approved Mimrylo (rusfertide) on August 28, 2026, for adults with polycythemia vera. In the VERIFY trial of 293 adults, 76.9% on Mimrylo required no phlebotomies during the 32-week period, compared with 32.9% on placebo. Takeda Pharmaceuticals America holds the NDA. Takeda said the approval does not change its forecast for the fiscal year ending March 31, 2027.
Claire Morgan · TickerGrove Healthcare Desk · Published 08-28-2026 · U.S. Food and Drug Administration
Sources
FDA news release, “FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder,” August 28, 2026. Takeda, “FDA Approves MIMRYLO (rusfertide) for Polycythemia Vera,” Osaka / Cambridge, August 28, 2026. Independently re-read.
Figures are from the FDA August 28, 2026 Mimrylo news release and Takeda’s August 28, 2026 MIMRYLO release, independently re-read. FDA 76.9% / 32.9% during the 32-week period and 19 mg stay on the FDA page. Takeda’s erythrocytosis / blood-cancer indication line and 56% / 16% adverse-reaction rates stay on Takeda’s page.
The FDA approved Mimrylo (rusfertide) on August 28, 2026, for adults with polycythemia vera. The rare blood disorder causes the body to make too many red blood cells. Those extra cells, the agency says, can thicken the blood and raise the risk of clots, stroke, and heart attack.
The FDA page and Takeda’s release are two documents. The agency approved Mimrylo for adults with polycythemia vera, a rare blood disorder, and printed 76.9% versus 32.9% who required no phlebotomies during the 32-week period. Takeda’s indication line is “for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.” Takeda prints 76.9% response in weeks 20–32 and does not print the 32.9% placebo figure or the 19 milligram starting dose. Takeda said the approval does not change its forecast for the fiscal year ending March 31, 2027.
A key treatment goal is keeping hematocrit — the share of blood that is red cells — below 45%, to cut cardiovascular risk. That often means phlebotomy: drawing blood from a vein, again and again. Some patients still need those draws on existing therapy.
The approval was granted to Takeda Pharmaceuticals America, Inc. Mimrylo received priority review.
What the FDA approved
Mimrylo “is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body.” By limiting the iron available to make new red cells, the agency says, the drug is meant to slow that overproduction.
Tanya Wroblewski, M.D., director of the Division of Nonmalignant Hematology in FDA’s Center for Drug Evaluation and Research, said: “People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction. Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.”
The weekly injection is aimed at that burden. It is not a promise that every patient will stop needing blood draws. The FDA news release does not print a list price or a ship date.
What VERIFY showed
Safety and efficacy were evaluated in VERIFY, a multicenter, randomized, double-blind, placebo-controlled phase 3 study of 293 adults with polycythemia vera who still needed frequent phlebotomies on standard care. Patients were randomized 1:1 to Mimrylo or placebo over 32 weeks.
Treatment started at 19 milligrams under the skin once a week and was titrated to keep hematocrit below 45%. Efficacy, the FDA says, was measured by the share of patients who did not meet criteria for phlebotomy between weeks 20 and 32. On the same page, 76.9% of patients on Mimrylo required no phlebotomies during the 32-week period, compared with 32.9% on placebo.
| Mimrylo | Placebo |
|---|---|
| 76.9% | 32.9% |
The most common adverse reactions on the FDA page were injection site reactions and anemia. The agency does not attach percentages to those reactions.
What Takeda said
Takeda’s own release, datelined Osaka and Cambridge on August 28, is a different document. Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) said the FDA approved the NDA for MIMRYLO (rusfertide) “for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.” That is Takeda’s indication line. The FDA page says “adults with polycythemia vera, a rare blood disorder.”
Takeda calls MIMRYLO a first-in-class hepcidin mimetic and says VERIFY showed 76.9% of patients achieved clinical response during weeks 20–32. Its release does not include the 32.9% placebo figure or the 19 milligram starting dose that appear on the FDA page.
On Takeda’s page, VERIFY is NCT05210790, a three-part global study of 293 patients over 156 weeks. The primary endpoint, as Takeda defines it, was the share of patients with a response in weeks 20–32, meaning they were not “phlebotomy eligible.” Eligibility in that protocol: confirmed hematocrit at least 45% and at least 3 percentage points above baseline, or hematocrit at least 48%. The randomized portion is complete; an open-label extension is ongoing.
Protagonist discovered MIMRYLO and led development through Phase 3, Takeda says. Takeda now holds exclusive global development and commercialization rights.
Takeda said the approval “does not result in any changes to Takeda’s consolidated financial forecast for the fiscal year ending March 31, 2027 (FY2026).” That is a forecast line, not an earnings print.
Takeda’s Important Safety Information lists the most common adverse reactions, above 15%, as injection site reactions (56%) and anemia (16%). It warns that MIMRYLO may raise platelet counts, can cause injection-site reactions including Grade 3 events, and may cause fetal harm. Takeda points to full Prescribing Information for the complete list.
Price, copay, and a U.S. availability date are not on either page.
A no-phlebotomy rate is not a promise that blood draws stop
The FDA approved Mimrylo for adults with polycythemia vera on August 28, 2026. In VERIFY, 76.9% of patients on Mimrylo required no phlebotomies during the 32-week period, compared with 32.9% on placebo. That is not a claim that every patient will stop needing blood draws.
Keep FDA 32.9% and 19 mg off Takeda’s page, and keep Takeda’s erythrocytosis / blood-cancer line off the FDA page
The FDA page prints two windows: patients who did not meet criteria for phlebotomy between weeks 20 and 32, and 76.9% versus 32.9% who required no phlebotomies during the 32-week period. Use the FDA page for 293 adults, 1:1, 19 milligrams once weekly, and hematocrit below 45%. Use Takeda for erythrocytosis in adults with PV, a blood cancer, NCT05210790, 156 weeks, 76.9% clinical response in weeks 20–32, open-label extension, 56% / 16% ISI rates, and the FY2026 forecast line for the year ending March 31, 2027.
Outside these documents
Neither opened page prints a list price, a copay, or a U.S. availability date. Takeda’s FY2026 forecast line is not an earnings print. The FDA page does not call polycythemia vera a blood cancer.
Corrections
We do not silently rewrite a published line. A correction is a new labeled piece, not an invisible edit.
Discuss this story. Join the TickerGrove community to talk companies, earnings, and markets, or request future coverage.
Sources & evidence
Primary documents used for this piece.
U.S. Food and Drug Administration approval of Mimrylo (rusfertide)
FDA Mimrylo approval page, August 28, 2026
FDA news release dated August 28, 2026
VERIFY as identified on Takeda’s page
Figures used in this article
VERIFY 76.9% / 32.9% required no phlebotomies during the 32-week period, from the FDA news release. Start dose 19 mg is FDA-only. Takeda’s 56% / 16% adverse-reaction rates stay on Takeda’s Important Safety Information.
Figure
293
- Entity
- Adults with polycythemia vera in VERIFY
- Period / as-of
- Phase 3 multicenter, randomized, double-blind, placebo-controlled study
- Unit / basis
- adults; FDA page count; randomized 1:1
Figure
76.9%
- Entity
- Mimrylo; required no phlebotomies during the 32-week period
- Period / as-of
- VERIFY; FDA page; during the 32-week period
- Unit / basis
- % of patients; versus 32.9% placebo; FDA page
Figure
32.9%
- Entity
- Placebo; required no phlebotomies during the 32-week period
- Period / as-of
- VERIFY; FDA page; during the 32-week period; not on Takeda’s page
- Unit / basis
- % of patients; versus 76.9% Mimrylo; FDA-only
Figure
19 mg
- Entity
- Mimrylo starting dose
- Period / as-of
- VERIFY; subcutaneously once weekly; titrated to keep hematocrit below 45%
- Unit / basis
- milligrams once weekly; FDA page; not on Takeda’s page
Figure
1:1
- Entity
- VERIFY randomization
- Period / as-of
- Mimrylo or placebo over 32 weeks; FDA page
- Unit / basis
- randomization ratio as printed
Figure
56%
- Entity
- MIMRYLO injection site reactions; Takeda Important Safety Information
- Period / as-of
- Most common adverse reactions above 15%; Takeda page
- Unit / basis
- %; company-said; versus FDA page with no attached percentage
Figure
16%
- Entity
- MIMRYLO anemia; Takeda Important Safety Information
- Period / as-of
- Most common adverse reactions above 15%; Takeda page
- Unit / basis
- %; company-said; versus FDA page with no attached percentage